Dr. Andrea Schlegel, Editorial Fellow, Transplantation
Bui K, Kilambi V, Rodrigue JR, Mehrotra S.
Transplantation 2019; 103 (5): 1051–1063
Colleagues from Chicago have analysed the kidney transplantation rate in the US and suggest to include the recipient’s health status for decision making and also in context of the critical demand of organs together with the increasing health deterioration of recipients during the prolonged waiting time for an organ. Authors obtain data of two large cohorts of kidney recipients from the UNOS database and assess the impact of the Karnofsky performance score (KPS) on outcomes after transplantation performed between 2007 and 2015. The KPS appeared as significant predictor for posttransplant survival and more specifically, recipients with a high KPS between 40 - 50 transplanted with excellent kidneys with a Kidney Donor Profile Index of 99 have a very high expected survival probability of > 90% in the first year. Importantly, recipients with a low KPS (for example between 10 to 30) have an impaired survival after transplantation, even if they receive kidneys of good quality.
Based on this analysis, future risk-adjusted allocation models will include the functional status of transplant candidates. Paralleled by similar findings from transplantation of other solid organs, such models will possibly improve listing and transplantation strategies to further increase optimal utilization of organs with a benefit for the entire population and subsequently achieve a reduction of the donor kidney discard rate.
June 25 - Dan Huh, the Wilf Family Term Assistant Professor in the Department of Bioengineering at University of Pennsylvania, focuses his research on creating organs-on-chips: specially manufactured micro-devices with human cells that mimic the natural cellular processes of organs. Huh’s lab has engineered chips that approximate the functioning of placentas and lung disease.
June 21 - Bronchoalveolar lavage (BAL) immune cells from patients with asthma treated with a short-acting beta-agonist demonstrated changes in gene expression that may not relate to disease mechanisms or be immediately matched by protein expression, according to the results of a study published in the American Journal of Respiratory and Critical Care Medicine.
June 20 - The primary cause of the loss of functionality in transplanted pancreatic islets is their low capacity to create new vessels to transport nutrients. Researchers from the University of Barcelona and IDIBAPS have led a study that identifies a protein as the potential modulator in the revascularization of pancreatic islets.
June 24 - Race-matched liver transplants significantly improved OS among black patients with early hepatocellular carcinoma, according to study results published in Journal of the American College of Surgeons.
June 18 - AML patients are generally older, more frail and unable to tolerate intensive chemotherapy. Despite initial complete remission (CR), they have worse outcomes due to frequent disease relapse, occurring often within first 12–18 months. The optimal consolidation treatment regimen for these patients has not yet been determined.
June 24 - Patients with HIV were less likely to be placed on the kidney transplant waitlist than patients without HIV, according to research presented at the American Transplant Congress. They also experienced longer wait-times from evaluation to listing.
The 3rd Joint Meeting of the Turkish Transplantation Society and the Turkic World Transplantation Society will be held in Tashkent, Uzbekistan on October 10-11, 2019. The Scientific and Local Organizing Committees, comprised of international transplantation leaders, have developed a program that reflects current problems and represents a collection of scientific, educational, and practical information. The meeting will be an exciting opportunity for transplant professionals to share their expertise as well as their concerns regarding the development of the field in their own countries.
ITS 2019 is set for Nov. 10-13 in Clearwater Beach, Florida. Keynote speakers include Katherine High, President and Head of R&D at Spark Therapeutics, and Ronald Germain, chief of Laboratory of Immune System Biology and Lymphocyte Biology Section at the National Institute of Allergy and Infectious Diseases National Institutes of Health.
Registration is open and preliminary program is available.